Full history for every metric is available with a Kvantra account
Love Pharma Inc. (LUV.CN)
Key financial summary
Financials in CAD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | CAD m | -4 | -4 | |||||
| Net profit | CAD m | -1 | 2 | -0 | -0 | -10 | -6 | -6 |
| EPS reported | CAD | -0.13 | -0.14 | |||||
| Operating cashflow per share | CAD | -0.04 | -0.04 | |||||
| Capex per share | CAD | 0.00 | 0.00 | |||||
| FCF per share | CAD | -0.04 | -0.04 | |||||
| Free cash flow | CAD m | -2 | -1 | |||||
| Net debt | CAD m | 0 | 0 | |||||
| Book value equity | CAD m | 0 | 0 | |||||
| Book value per share | CAD | 0.00 | 0.00 | |||||
| Number of shares | m | 41.33 | 50.42 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 11.00 | 4.40 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -1.37 | 0.00 | |||||
| EV/EBITDA LTM | x | -1.33 | -0.06 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -266.49% | -666.22% | |||||
| FCF Yield | % | -72.80% | - | |||||
| Quality | ||||||||
| ROE | % | -2932.1% | -787.40% | |||||
| ROIC | % | -743.02% | -743.02% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -10.36 | -7.83 | |||||
| Net Debt/EBITDA | x | -0.06 | -0.06 | |||||
| EBIT/Net interest | x | -186.02 | -186.02 | |||||
| Net debt/market cap | % | 5.02% | - | |||||
| Net debt/Equity | x | 0.55 | 1.67 | |||||
| Gross debt/equity | x | 0.77 | 1.71 | |||||
Company overview
Love Pharma Inc. specializes in advancing mental and sexual well-being through the licensing and distribution of psychedelic and hemp-derived products. These offerings are available across North America, the United Kingdom, and Europe. Its current product portfolio includes BLOOM, a gel formulated for female arousal, and AURALIEF, a sublingual strip infused with cannabis. The company was established in 2020 and is headquartered in Vancouver, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Love Pharma Inc. (LUV.CN)
Love Pharma Inc. specializes in advancing mental and sexual well-being through the licensing and distribution of psychedelic and hemp-derived products. These offerings are available across North America, the United Kingdom, and Europe. Its current product portfolio includes BLOOM, a gel formulated for female arousal, and AURALIEF, a sublingual strip infused with cannabis. The company was established in 2020 and is headquartered in Vancouver, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free